RT @KirbyInstitute: David Cooper was a world-leading infectious diseases researcher & doctor. Sadly, he passed away in 2018. He believed ac…
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
HIV and cardiovascular disease
The afternoon session: O21 - HIV and co-morbidity started with two speakers who complemented each others presentations very well.
Dr Paddy Mallon provided an excellent overview of the cardiovascular risk factors associated not only with HIV itself, but the ART used in its management - especially abacavir.
Importantly he provided an overview on the potential role of increased platelet activity and their role in increasing the risk of vascular events and thrombosis. He concluded with reference to a current trial of pitavastatin to assess its potential in reducing hyperlypidaemic risk.
Dr Janine Trevillyan followed on with an excellent overview of why HIV patients are at increased risk of CVD including dyslipidaemias, immune activation, platelet activity and other risk factors such as a higher incidence of smoking and diabetes.
Janine then provided an overview of her current research activities on platelet derived soluble glycoprotein VI (sGPVI), where she described the observation that sGPVI levels are reduced in the month preceding a cardiac event in HIV positive patients and may have an important role in promoting cardiovascular disease in this population. It was postulated that this reduction in levels may be linked to a pathological process leading to MI, or sign of an unstable plaque.